Realigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025 Exploring partnerships for continued development of Lunre+Camo and other assets CAMBRIDGE, Mass. & MONTREAL / Jan 09, 2025 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading... Read More

Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with... Read More

Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET CAMBRIDGE, Mass. & MONTREAL / Dec 10, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination... Read More

CAMBRIDGE, Mass. & MONTREAL / Nov 12, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been executed to advance the development of camonsertib as an anticancer agent in collaboration with the Cancer Therapy Evaluation Program (CTEP) of the US National... Read More

On track to report data from the ongoing MYTHIC dose expansion clinical trial at the recommended Phase 2 dose (RP2D) at a company event in December 2024, with the plan to begin a registrational trial in 2025 Presented updated positive safety and tolerability results from the Phase 1 MYTHIC clinical trial at the 36 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Dosed first patient in Phase 1 POLAR... Read More

Data presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAMBRIDGE, Mass. & MONTREAL / Oct 23, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data highlighting the benefits of its individualized schedule for the management of anemia in the Phase 1 MYTHIC clinical trial... Read More

CAMBRIDGE, Mass. & MONTREAL / Oct 14, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s Phase 1 (POLAR) clinical trial evaluating RP-3467, a Polθ ATPase inhibitor, alone and in combination with the poly-ADP ribose polymerase (PARP) inhibitor, olaparib. RP-3467 is... Read More

CAMBRIDGE, Mass. & MONTREAL / Sep 30, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported data highlighting the clinical benefits of camonsertib, a potential best-in-class oral small molecule ATR inhibitor, combined with palliative radiation for the treatment of metastatic tumors harboring an... Read More

Data presented at AACR’s Ovarian Cancer Research Symposium confirm that ovarian and endometrial cancers with CCNE1 amplifications, FBXW7 or PP2R1A mutations carry poor prognosis Significant survival disparities were identified in patients harboring lunresertib- and camonsertib-sensitizing biomarkers, including CCNE1 amplifications or mutations in FBXW7 or PPP2R1A CAMBRIDGE, Mass. & MONTREAL / Sep 23, 2024 / Business Wire /... Read More

CAMBRIDGE, Mass. & MONTREAL / Sep 13, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will share new data from Module 1 of its ongoing Phase 1/2 TRESR clinical trial during an oral presentation on September 14 at the European Society for Medical Oncology Congress (ESMO), held in Barcelona, Spain. TRESR... Read More

Focuses Company’s resources on its deep clinical oncology pipeline Positioned to advance four clinical programs through multiple upcoming milestones CAMBRIDGE, Mass. & MONTREAL / Aug 28, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the strategic reprioritization of its research and development activities to... Read More

CAMBRIDGE, Mass. & MONTREAL / Aug 27, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September. Details for the presentations are as follows: Morgan Stanley 22 nd Annual Global Healthcare Conference Fireside Chat Date:... Read More

Reiterated guidance on data readout from MYTHIC trial evaluating lunresertib and camonsertib in patients with platinum-resistant ovarian and endometrial cancers in Q4 2024 Granted Fast Track designation by the FDA for lunresertib in combination with camonsertib in platinum-resistant ovarian cancer Presented positive initial data from Phase 1 MINOTAUR clinical trial evaluating lunresertib in combination with FOLFIRI in... Read More

Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan exposure Prolonged clinical benefit in patients with CRC, with 40% of irinotecan-naïve patients receiving treatment for greater than nine months Preliminary RP2D established as 60mg BID lunresertib continuous plus standard FOLFIRI Safety profile of combination consistent with FOLFIRI... Read More

CAMBRIDGE, Mass. & MONTREAL / Jun 10, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial. “Camonsertib has demonstrated a promising signal of prolonged progression free... Read More

CAMBRIDGE, Mass. & MONTREAL / Jun 04, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to lunresertib in combination with camonsertib for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A-mutated... Read More

CAMBRIDGE, Mass. & MONTREAL / Jun 03, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 2:40 p.m. Eastern Time in Miami, FL. A live webcast of the... Read More

CAMBRIDGE, Mass. & MONTREAL / May 29, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced solid tumors has been selected for a poster presentation at the European Society of Medical... Read More

Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20... Read More

MONTREAL & LAUSANNE, Switzerland / Apr 30, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced that the first patient has been dosed... Read More

LAUSANNE, Switzerland & MONTREAL / Apr 30, 2024 / Business Wire / Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases , and Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced that the first patient has been dosed in Module 4 of the... Read More

CAMBRIDGE, Mass. & MONTREAL / Apr 26, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to... Read More

CAMBRIDGE, Mass. & MONTREAL / Feb 29, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two upcoming investor conferences. Details for the presentations are as follows. TD Cowen 44 th Annual Healthcare Conference Panel Discussion: Gynecological Cancers... Read More

CAMBRIDGE, Mass. & MONTREAL / Feb 28, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023. “2023 was a year of substantial progress for Repare. We advanced each of the four programs in our portfolio and set the stage for meaningful data... Read More

RP-1664 is a Potential First-in-Class, Selective, PLK4 Inhibitor CAMBRIDGE, Mass. & MONTREAL / Feb 15, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s Phase 1 LIONS (P L K4 Inh i bit o r i n Advanced S olid Tumors) clinical trial evaluating RP-1664, a potential... Read More

Repare will regain control of its potential best-in-class oral small molecule ATR inhibitor CAMBRIDGE, Mass. & MONTREAL / Feb 12, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that it will regain global development and commercialization rights to camonsertib (RP-3500), a potential best-in-class oral small... Read More

Milestone payment triggered by dosing of the first patient in camonsertib-based arm in Roche’s Phase 2 TAPISTRY platform clinical trial Repare is eligible to receive up to $1.2 billion in potential milestones, plus royalties on global net product sales CAMBRIDGE, Mass. & MONTREAL / Jan 25, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology... Read More

CAMBRIDGE, Mass. & MONTREAL / Jan 08, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. “We significantly advanced our pipeline in 2023 and presented strong data from key programs, notably for lunresertib in combination with camonsertib, and for... Read More

Collaborative clinical study will investigate a novel combination of lunresertib, Repare’s first-in-class PKMYT1 inhibitor, and Debio 0123, Debiopharm’s potent, brain-penetrant inhibitor of WEE1 MONTREAL & LAUSANNE, Switzerland / Jan 04, 2024 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has entered into a... Read More

CAMBRIDGE, Mass. & MONTREAL / Dec 29, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that its executive officers (collectively, the “Executives”) have established new Automatic Securities Disposition... Read More

RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies RP-3467 demonstrated complete, sustained regressions preclinically in combination with PARPi, and compelling anti-tumor activity in combination with radioligand therapy (RLT) and chemotherapy Company expects to initiate clinical trials of RP-1664 in 1H 2024 and RP-3467 in 2H 2024 Repare to... Read More

Presented positive initial data from ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors Repare to host conference call and webcast to discuss latest data from its preclinical programs and overall pipeline, November 15 th , 2023 at 8:00 a.m. ET CAMBRIDGE, Mass. &... Read More

Event to be webcast live on Wednesday, November 15 at 8:00 a.m. ET CAMBRIDGE, Mass. & MONTREAL / Nov 07, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, a newly designated Polθ... Read More

CAMBRIDGE, Mass. & MONTREAL / Nov 06, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details for the fireside chats are as follows: Stifel 2023 Healthcare Conference Date: Tuesday, November 14, 2023 Time: 8:35... Read More

Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all selected genotypes Overall response of 33.3% across all tumor types and 50% RECIST response in patients with heavily pre-treated gynecologic tumors, including endometrial, ovarian and cervical, at the preliminary recommended phase 2 dose Encouraging safety and tolerability profile observed as... Read More

Conference call and live webcast on Friday, October 13, 2023 at 5:30 p.m. ET CAMBRIDGE, Mass. & MONTREAL / Oct 03, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to share initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial that will be... Read More

CAMBRIDGE, Mass. & MONTREAL / Sep 19, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will present initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial in a plenary session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held... Read More

CAMBRIDGE, Mass. & MONTREAL / Sep 06, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare Conference on Wednesday, September 13, 2023, at 11:30 a.m. Eastern Time in New York, NY. A live... Read More

Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types, genomic alterations, PARPi choice or platinum resistance Roche has included a camonsertib-based arm in its Phase 2 TAPISTRY study and its Phase 1/2 Morpheus Lung study of multiple combinations in metastatic non-small cell lung cancer Reported clinical proof of concept for lunresertib... Read More

CAMBRIDGE, Mass. & MONTREAL / Jun 08, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time in Dana... Read More

Findings from the ongoing Phase 1 MYTHIC study demonstrated a favorable and distinctive tolerability profile for monotherapy lunresertib Monotherapy antitumor activity observed, including confirmed partial response and several patients with long stable disease Identified both intermittent and continuous schedules to enable combination studies Encouraging early responses across gemcitabine, camonsertib and FOLFIRI clinical... Read More

CAMBRIDGE, Mass. & MONTREAL / Jun 06, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that data from the ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526, partnered with Roche), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein... Read More

Event to be webcast live on Wednesday, June 7, 2023 at 4:30 p.m. ET CAMBRIDGE, Mass. & MONTREAL / Jun 02, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to... Read More

CAMBRIDGE, Mass. & MONTREAL / May 22, 2023 / Business Wire / Repare Therapeutics Inc. , (Nasdaq: RPTX), (“Repare”, or “the Company”), a leading clinical-stage precision oncology company, today announced that, in connection with the appointment of Daniel Belanger as the Company’s EVP, Human Resources, the Company granted Mr. Belanger an inducement stock option to purchase an aggregate of 240,000 of the Company’s common... Read More

Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting Camonsertib combination therapy showed 48% CBR across tumor types regardless of choice of PARP inhibitor or platinum resistance, with a favorable safety and tolerability profile Company on track to report initial RP-6306 monotherapy data from Phase 1 MYTHIC clinical... Read More

CAMBRIDGE, Mass. & MONTREAL / Apr 28, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2023. Concurrent with Dr. Molineaux’s appointment as of the date of... Read More

Camonsertib PARPi combinations demonstrated 48% CBR in patients with unmet medical needs, across tumor types, and regardless of PARPi partner or platinum resistance, with a favorable safety and tolerability profile Combination results showed most benefit in late-line ovarian cancer demonstrating 32% overall response, 58% CBR and mPFS of approximately 7 months Early ctDNA molecular responses in 66% of evaluable patients... Read More

CAMBRIDGE, Mass. & MONTREAL / Mar 14, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the... Read More

CAMBRIDGE, Mass. & MONTREAL / Feb 02, 2023 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in February and March. Details for the fireside chats are as follows: Guggenheim Oncology Conference Date: Thursday, February 9, 2023 Time:... Read More

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co., Ltd. (“Ono”). The payment reflects achievement of a specified research trigger, under the companies’ 2019 Strategic Partnership Agreement (“Ono Agreement”).... Read More